TABLE 2.
Mouse typea | Mean clinical score (day 10) ± SD | Lymphoproliferation (mean cpm ± SD)b
|
Mean IFN-γ concn (ng/ml)c ± SD with:
|
||||
---|---|---|---|---|---|---|---|
Responders plus uninfected stimulators | Responders plus HSV stimulators | Responders plus OVA stimulators | UV-HSV | OVA | ConA | ||
OT2xRAG1−/− | 2.4 ± 0.5 | 116 ± 90 | 110 ± 48 | 19,680 ± 1,450 | <1 | 6.8 ± 1.3 | 14.8 ± 2.0 |
B6 | 0 | 270 ± 120 | 20,590 ± 1,120 | 280 ± 80 | 4.9 ± 0.5 | <1 | 16.5 ± 1.5 |
C57BL/6 SCID | 2.9 ± 0.8 | 210 ± 110 | 30,897 ± 1,148 | 180 ± 50 | 8.8 ± 0.6 | <1 | 18.3 ± 1.4 |
Mice (n = 6) were infected with 2 × 106 PFU of HSV-1 RE on scarified corneas and then scored for clinical lesions using the slit-lamp microscope as described previously. The data are represented as the mean clinical scores ± the standard deviations. Ocularly infected C57BL/6 SCID mice reconstituted with B6 HSV immune splenocytes were used as positive control for inducing HSK.
Mice (n = 6) were terminated at day 10 postinfection, and spleen and lymph node cells were used in a lymphoproliferation assay as described previously. The data are represented as the means cpm incorporated ± the standard deviations.
Splenocytes (2 × 106 cells/ml) from mice were restimulated in vitro with UV-irradiated HSV (UV-HSV; MOI = 5.0), OVA (10 μg/ml), or ConA (2 μg/ml), and the supernatant was assayed for IFN-γ by ELISA.